Citations (121)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Batool Haider, Amy K O’Sullivan, Leona Bessonova, Elizabeth Keane, Eric Achtyes, Philip D Harvey, John M Kane, Stephen R Saklad, Jeffrey P Trotter, Amy Claxton, Tiffany Polak, James McGrory, Wahidullah Noori, Asia Sikora Kessler, Aaron Yarlas & Dawn Velligan. (2023) Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic. Neuropsychiatric Disease and Treatment 19, pages 623-634.
Read now
Read now
Stefano Bramante, Gabriele Di Salvo, Giuseppe Maina & Gianluca Rosso. (2023) Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs. Neuropsychiatric Disease and Treatment 19, pages 519-530.
Read now
Read now
Dusica Hadzi Boskovic, Shuting Liang, Purva Parab, Emily Wiggins & Joshua N Liberman. (2023) Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization. ClinicoEconomics and Outcomes Research 15, pages 487-498.
Read now
Read now
Molly McVoy & Jennifer B. Levin. (2023) Updated strategies for the management of poor medication adherence in patients with bipolar disorder. Expert Review of Neurotherapeutics 23:4, pages 365-376.
Read now
Read now
David Fraguas, David Almenta Gallego, Sergio Arques-Egea, Marcos Gómez-Revuelta, Carlos Gómez Sánchez-Lafuente, Daniel Hernández Huerta, Daniel Núñez Arias, Beatriz Oda Plasencia-García, Carlos Parro Torres, Samuel Leopoldo Romero-Guillena, Elena Ros Cucurul & Cecilio Alamo. (2023) Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International Journal of Psychiatry in Clinical Practice 27:1, pages 82-91.
Read now
Read now
Jeffrey M Cochran, Hui Fang, John G Sonnenberg, Elan A Cohen, Jean-Pierre Lindenmayer & J Corey Reuteman-Fowler. (2022) Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with Schizophrenia. Neuropsychiatric Disease and Treatment 18, pages 1521-1534.
Read now
Read now
Takeshi Inoue, Hiromi Sano, Yoshitsugu Kojima, Sakiko Yamada & Osamu Shirakawa. (2021) Real-World Treatment Patterns and Adherence to Oral Medication Among Patients with Bipolar Disorders: A Retrospective, Observational Study Using a Healthcare Claims Database. Neuropsychiatric Disease and Treatment 17, pages 821-833.
Read now
Read now
Jane Loftus, Yong Chen, Jose Ma. J. Alvir, Lei Chi, Shibasish Dasgupta, Anu Gupta & Michael P. Wajnrajch. (2021) Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency. Current Medical Research and Opinion 37:12, pages 2141-2150.
Read now
Read now
Georgios D. Kotzalidis, Chiara Rapinesi, Chiara Chetoni & Sergio De Filippis. (2021) Aripiprazole IM depot as an option for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 22:11, pages 1407-1416.
Read now
Read now
Martina Curto, Francesco Fazio, Martina Ulivieri, Serena Navari, Luana Lionetto & Ross J Baldessarini. (2021) Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment. Expert Opinion on Pharmacotherapy 22:9, pages 1143-1155.
Read now
Read now
Michael L. Ganz, Ameya Chavan, Rahul Dhanda, Michael Serbin & Charles Yonan. (2021) Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. Journal of Medical Economics 24:1, pages 103-113.
Read now
Read now
Michael J Doane, Martha Sajatovic, Peter J Weiden, Amy K O’Sullivan, Stephen Maher, Jakob B Bjorner, Asia Sikora Kessler, Julia Carpenter-Conlin, Leona Bessonova & Dawn I Velligan. (2020) Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey. Patient Preference and Adherence 14, pages 2043-2054.
Read now
Read now
Carlos De las Cuevas & Jose de Leon. (2020) Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics. Patient Preference and Adherence 14, pages 1823-1842.
Read now
Read now
Yoshiteru Takekita, Sachie Inoue, Kenji Baba & Tadashi Nosaka. (2020) Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database. Neuropsychiatric Disease and Treatment 16, pages 2871-2879.
Read now
Read now
Adrian Preda & Bryan B. Shapiro. (2020) A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opinion on Drug Safety 19:12, pages 1529-1538.
Read now
Read now
Mami Kasahara-Kiritani, Amish Chaturvedi, Ataru Inagaki, Akihide Wakamatsu & Wonjoo Jung. (2020) Budget impact analysis of long acting injection for schizophrenia in Japan. Journal of Medical Economics 23:8, pages 848-855.
Read now
Read now
Rahul Dhanda, Della Varghese, Vijay R Nadipelli, Maurizio Fava, Namita Joshi, Caitlyn T Solem, James A Graham, Susan M Learned & Christian Heidbreder. (2019) Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Preference and Adherence 13, pages 1037-1050.
Read now
Read now
Xue Song, Antoine C. El Khoury, Matthew Brouillette, David Smith & Kruti Joshi. (2019) Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of Medical Economics 22:11, pages 1105-1112.
Read now
Read now
Jennifer Munday, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan & Michael S. Broder. (2019) Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Current Medical Research and Opinion 35:7, pages 1231-1239.
Read now
Read now
Michael S. Broder, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan & Irina Yermilov. (2019) Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder. Journal of Medical Economics 22:1, pages 63-70.
Read now
Read now
Mallik Greene, Chakkarin Burudpakdee, Arpamas Seetasith, Michael Behling & Holly Krasa. (2019) Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers. Current Medical Research and Opinion 35:1, pages 97-103.
Read now
Read now
Articles from other publishers (100)
V. V. Stanovaya, Z. T. Guseynova, M. V. Ivanov & E. V. Bigday. (2023) The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of anti-resistant effects. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY 57:4, pages 120-130.
Crossref
Crossref
Kristin Richards, Michael Johnsrud, Christopher Zacker & Rahul Sasané. (2023) One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication. Administration and Policy in Mental Health and Mental Health Services Research.
Crossref
Crossref
Cristina Micale, Su Golder, Karen O’Connor, Davy Weissenbacher, Robert Gross, Sean Hennessy & Graciela Gonzalez-Hernandez. (2023) Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media. Drug Safety.
Crossref
Crossref
Samuel R. BuntingKristen ChalmersDaniel YohannaRoyce Lee. (2023) Prescription of Long-Acting Injectable Antipsychotic Medications Among Outpatient Mental Health Care Service Providers. Psychiatric Services 74:11, pages 1146-1153.
Crossref
Crossref
Jacqueline Pesa, Zhiwen Liu, Alex Z. Fu, Alicia K. Campbell & Richard Grucza. (2023) Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia. Schizophrenia Research 261, pages 170-177.
Crossref
Crossref
Yixian Xu, Xinkai Zheng, Yuanjie Li, Xinmiao Ye, Hongtao Cheng, Hao Wang & Jun Lyu. (2023) Exploring patient medication adherence and data mining methods in clinical big data: A contemporary review. Journal of Evidence-Based Medicine 16:3, pages 342-375.
Crossref
Crossref
Jing‐Hao Hsu, Stephane Wen‐Wei Ku, Tsai‐Wei Chen, Chia‐Wen Li, Poyao Huang, Huei‐Jiuan Wu, Adam Bourne & Carol Strong. (2023) Preferences for long‐acting pre‐exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey. Journal of the International AIDS Society 26:9.
Crossref
Crossref
Ute Richarz, John Han, Ya-Mei Bai, Eric Yu-Hai Chen, Young Chul Chung, Venu Gopal Jhanwar, Sung-Wan Kim, Ahmad Hatim SulaimanKarl Knight & Srihari Gopal. (2023) Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study. Medicine 102:34, pages e34623.
Crossref
Crossref
Junichi Goto, Masahiro Shono, Yasuhisa Abe, Yasutaka Fujita, Keishi Ueda, Binchi Yoshida & Yoshihiro Nabeshima. (2023)
Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: A multicenter
1‐year
retrospective mirror image study
. Neuropsychopharmacology Reports.
Crossref
Crossref
Srinivasan Tirupati. (2023) Rehospitalisation of Patients with Enduring Schizophrenia After Discharge from a Long-Stay Inpatient Psychiatric Rehabilitation Unit. Journal of Psychosocial Rehabilitation and Mental Health.
Crossref
Crossref
Qian Li, Xin Li, Chong Ye, Miaomiao Jia & Tianmei Si. (2023) Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis. CNS Drugs 37:8, pages 695-713.
Crossref
Crossref
Christina J. Chen & Wanda Hilliard. (2023) Text Message Reminders for Long-Acting Injectable Antipsychotics in Patients with Schizophrenia Spectrum Disorders. Journal of the American Psychiatric Nurses Association.
Crossref
Crossref
John M. Kane, Anna Chen, Sangtaeck Lim, Marko A. Mychaskiw, Marc Tian, Yitong Wang, Mark Suett & Jose M. Rubio. (2023) Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. International Clinical Psychopharmacology 38:4, pages 240-248.
Crossref
Crossref
Julia Spaton Goppers, Ellenor Mittendorfer-Rutz, Alexis E. Cullen, Christopher Jamil de Montgomery, Antti Tanskanen, Marie Norredam & Heidi Taipale. (2023) Antipsychotic treatment patterns in refugees and their Swedish-born peers with first-episode non-affective psychosis: findings from the REMAIN study. BJPsych Open 9:3.
Crossref
Crossref
J. E. Siegel-Ramsay, S. J. Sharp, C. J. Ulack, K. S. Chiang, T. Lanza di Scalea, S. O’Hara, K. Carberry, S. M. Strakowski, J. Suarez, E. Teisberg, S. Wallace & J. R. C. Almeida. (2023) Experiences that matter in bipolar disorder: a qualitative study using the capability, comfort and calm framework. International Journal of Bipolar Disorders 11:1.
Crossref
Crossref
Andrea L. Murphy, Sowon Suh, Louise Gillis, Jason Morrison & David M. Gardner. (2023) Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review. Pharmacy 11:2, pages 45.
Crossref
Crossref
Carey Pike & Linda-Gail Bekker. (2023) Interrogating the promise of long-acting HIV pre-exposure prophylaxis. Trends in Molecular Medicine 29:2, pages 93-98.
Crossref
Crossref
Emily Groenendaal, Sean Lynch, Rhea Dornbush, Lidia Klepacz & Stephen Ferrando. (2023) Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: A naturalistic cohort study. Journal of Psychiatric Research 158, pages 273-280.
Crossref
Crossref
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, Greta Silvia Carnevali, Agnese Tringali, Roberto Nava, Massimo Clerici & Enrico Capuzzi. (2023) High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. Biomedicines 11:2, pages 314.
Crossref
Crossref
Paballo Mataboge, Susan Nzenze, Nqaba Mthimkhulu, Mbali Mazibuko, Alison Kutywayo, Vusile Butler, Nicolette Naidoo & Saiqa Mullick. (2023) Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa. Frontiers in Reproductive Health 4.
Crossref
Crossref
Gabriel G. Edwards, Ayako Miyashita-Ochoa, Enrico G. Castillo, David Goodman-Meza, Ippolytos Kalofonos, Raphael J. Landovitz, Arleen A. Leibowitz, Craig Pulsipher, Ed El Sayed, Steven Shoptaw, Chelsea L. Shover, Michelle Tabajonda, Yvonne S. Yang & Nina T. Harawa. (2022) Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS and Behavior 27:1, pages 10-24.
Crossref
Crossref
Steffen Moritz, Eva Carolin Krieger, Francesca Bohn, Julia Elmers & Ruth VeckenstedtSteffen Moritz, Eva Carolin Krieger, Francesca Bohn, Julia Elmers & Ruth Veckenstedt. 2023. MKT+. MKT+
9
57
.
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2022) The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up. Biomedicines 11:1, pages 42.
Crossref
Crossref
Howard C. Margolese, Matthieu Boucher, Francois Therrien & Guerline Clerzius. (2022) Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study. BMC Psychiatry 22:1.
Crossref
Crossref
Michael J. Doane, Leona Bessonova, Haley S. Friedler, Kathleen M. Mortimer, Harry Cheng, Thomas Brecht, Amy K. O’Sullivan, Hannah Cummings, David McDonnell & Jonathan M. Meyer. (2022) Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry 22:1.
Crossref
Crossref
Nagesh Pai, Mustafa Acar, Prabhjot Juneja, Mahsa Hosseini Kouhkamari, Sinthuja Siva & Judy Mullan. (2022) Antipsychotic prescribing patterns in Australia: a retrospective analysis. BMC Psychiatry 22:1.
Crossref
Crossref
Jie Liu, Qian Wang, Lei Su, Limin Yang, Lianyong Zou & Ludong Bai. (2022) A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China. BMC Psychiatry 22:1.
Crossref
Crossref
Muhammad Youshay Jawad & Roger S. McIntyre. (2022) Barriers to managing bipolar I disorder with long-acting injectable antipsychotics. European Neuropsychopharmacology 64, pages 4-6.
Crossref
Crossref
Amy M. VandenBerg. (2022) An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Mental Health Clinician 12:5, pages 270-281.
Crossref
Crossref
Steven KheloussiJohn OberlinJrJrMadison TraugerNicholas D Testa. (2022) Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics. Journal of Managed Care & Specialty Pharmacy 28:10, pages 1130-1137.
Crossref
Crossref
Miguel Bernardo, Gisela Mezquida, Paula Ferré, Bibiana Cabrera, Mercè Torra, Ana Maria Lizana & Mercè Brunet. (2022) Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency. Revista de Psiquiatría y Salud Mental (English Edition) 15:4, pages 230-237.
Crossref
Crossref
Miguel Bernardo, Gisela Mezquida, Paula Ferré, Bibiana Cabrera, Mercè Torra, Ana Maria Lizana & Mercè Brunet. (2022) Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency. Revista de Psiquiatría y Salud Mental 15:4, pages 230-237.
Crossref
Crossref
Andrea Fagiolini, Eugenio Aguglia, Andrea Ballerini, Gaetano Callista, Bernardo Carpiniello, Massimo Clerici, Giulio Corrivetti, Alessandro Cuomo, Pasquale De Fazio, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Daniele La Barbera, Claudio Mencacci, Gino Montagnani, Giorgio Pigato, Jarno Vannucchi & Antonio Vita. (2022) Treatment persistence with aripiprazole once monthly: a 4-year follow-up. Annals of General Psychiatry 21:1.
Crossref
Crossref
Akitoyo Hishimoto, Norio Yasui-Furukori, Daisuke Sekine, Miyuki Matsukawa & Sakiko Yamada. (2022) Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study. Advances in Therapy 39:9, pages 4299-4314.
Crossref
Crossref
Amber Martin, Leona Bessonova, Rachel Hughes, Michael J. Doane, Amy K. O’Sullivan, Kassandra Snook, Allie Cichewicz, Peter J. Weiden & Philip D. Harvey. (2022) Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States. Advances in Therapy 39:9, pages 3933-3956.
Crossref
Crossref
Young-Chul Chung, Yen Kuang Yang, Ahmad Hatim Sulaiman, Paul Bergmans & Wilson Tan. (2022) Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting. Clinical Psychopharmacology and Neuroscience 20:3, pages 427-439.
Crossref
Crossref
Oscar Ribero, Anne-Marie Castilloux, Lina Maria Agudelo, Gerardo Machnicki, Vanesa Morales, Sergio Perocco, Genaro Castillon & Yola Moride. (2022) Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility. Revista Colombiana de Psiquiatría.
Crossref
Crossref
M. Holm, A. Tanskanen, M. Lähteenvuo, J. Tiihonen & H. Taipale. (2022) Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder. European Neuropsychopharmacology 61, pages 36-42.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2022) Effectiveness of More Personalized, Case-Managed, and Multicomponent Treatment for Patients with Severe Schizophrenia Compared to the Standard Treatment: A Ten-Year Follow-Up. Journal of Personalized Medicine 12:7, pages 1101.
Crossref
Crossref
Betül UYAR, Abdullah ATLI & Derya GÜL BİLEN. (2022) Clinical use of long-acting antipsychotics for the treatment of bipolar disorder type I patientsBipolar bozukluk tip I hastalarının tedavisinde uzun etkili antipsikotiklerin klinik kullanımı. Cukurova Medical Journal 47:2, pages 844-851.
Crossref
Crossref
Jared T Metropulos, Benjamin R Goldstein & Benjamin Hodapp. (2022) Recognition and Treatment Challenges of Acute Clozapine Withdrawal Syndrome: A Case Report. Cureus.
Crossref
Crossref
Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Crossref
Paulo Sousa Martins, Filipa Caldas, Catarina Oliveira, Jorge Mota & Marta Gonçalves. (2022) A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder. Psychiatry Research 312, pages 114581.
Crossref
Crossref
Ashley J. Maister, Caitlin McCarthy, Lee G. Ruszczyk, Rachael Evans & Megan E. Maroney. (2022) Impact of integrated behavioral health services on adherence to long-acting injectable antipsychotics. Journal of Integrated Care 30:3, pages 225-236.
Crossref
Crossref
Donica Janzen, James M. Bolton, Christine Leong, I fan Kuo & Silvia Alessi-Severini. (2022) Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort. Frontiers in Pharmacology 13.
Crossref
Crossref
Hannah W. Haddad, Elena Boardman, Brooke Williams, Rama Mouhaffel, Adam M. Kaye & Alan D. Kaye. (2022) Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review. Health Psychology Research 10:2.
Crossref
Crossref
Rosaria Di Lorenzo, Anita Iorio, Margherita Pinelli, Federica Maria Magarini, Mattia Marchi, Andrea Sacchetti, Chiara Calogero, Gian Galeazzi, Paola Ferri, Sergio Rovesti & Alessandro Minarini. (2022) Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. Neuropsychiatric Disease and Treatment Volume 18, pages 829-846.
Crossref
Crossref
Justin Faden & Leslie Citrome. (2022) How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia. Clinical Therapeutics 44:4, pages 476-479.
Crossref
Crossref
Dean Najarian, Panna Sanga, Steven Wang, Pilar Lim, Arun Singh, Mary Jane Robertson, Kristin Cohen, Alain Schotte, Ruth Milz, Raja Venkatasubramanian, Huybrecht T’Jollyn, David P Walling, Silvana Galderisi & Srihari Gopal. (2022) A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. International Journal of Neuropsychopharmacology 25:3, pages 238-251.
Crossref
Crossref
Ofer Agid, Gary Remington, Carmen Fung, Natalie M. Nightingale, Marc Duclos & Gregory J. Anger. (2021) Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study. The Canadian Journal of Psychiatry 67:3, pages 226-234.
Crossref
Crossref
Charmi Patel, Ahong Huang, Li Wang, Yoshita Paliwal & Kruti Joshi. (2022) Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs. Advances in Therapy 39:3, pages 1199-1214.
Crossref
Crossref
Huiying Wang, Fengju Yao, Hailing Wang, Changhong Wang & Zhengjun Guo. (2022) Medication Adherence and Influencing Factors Among Patients With Severe Mental Disorders in Low-Income Families During COVID-19 Outbreak. Frontiers in Psychiatry 12.
Crossref
Crossref
Sung-Yong Park, Won-Myong Bahk, Young Sup Woo, Jong-Hyun Jeong, Bo-Hyun Yoon, Jeong Seok Seo, IL Han Choo, Chan-Mo Yang, Won Kim, Jung Goo Lee, Se-Hoon Shim, Myung Hun Jung, Duk-In Jon, Moon-Doo Kim & InKi Sohn. (2022) Korean Medication Algorithm Project for Bipolar Disorder 2022: Treatment Strategy According to Safety and Tolerability. Journal of Korean Neuropsychiatric Association 61:4, pages 274.
Crossref
Crossref
Olivier Corbeil, Anne-Marie Essiambre, Laurent Béchard, Audrey-Anne Roy, Maxime Huot-Lavoie, Sébastien Brodeur, Ranjith Chandrasena, Chantale Thériault, Candice Crocker, Jean-Pierre Melun, Phil Tibbo, Marie-France Demers & Marc-André Roy. (2022) Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation. Therapeutic Advances in Psychopharmacology 12, pages 204512532211360.
Crossref
Crossref
Péter Takács, Péter Kunovszki, Valeria Timtschenko, László Fehér, Tamás Balázs, Ramóna Hegyi, Pál Czobor & István Bitter. (2022) Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update. Schizophrenia Bulletin Open 3:1.
Crossref
Crossref
Linda‐Gail Bekker, Carey Pike & Sharon L. Hillier. (2022) HIV prevention: better choice for better coverage. Journal of the International AIDS Society 25:1.
Crossref
Crossref
Ana Catalan, Lorena García, Sergio Sanchez‐Alonso, Patxi Gil, Marina Díaz‐Marsá, José Manuel Olivares, Tania Rivera‐Baltanás, Jorge Pérez‐Martín, Miguel Ángel González Torres, Santiago Ovejero, Meritxell Tost, Daniel Bergé, Alfonso Rodríguez & Javier Labad. (2020) Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first‐episode psychosis. Early Intervention in Psychiatry 15:6, pages 1584-1594.
Crossref
Crossref
Claus Wolff-Menzler, Jörg Mahlich, Kerstin Olbrich, Adrian Wilk & Antonie Wimmer. (2021) Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antipsychotika. Gesundheitsökonomie & Qualitätsmanagement 26:06, pages 302-309.
Crossref
Crossref
Sun Lee & Shaina Schwartz. (2021) Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies. Psychiatry Research 306, pages 114277.
Crossref
Crossref
Charles Dorflinger, Colleen LeHew, Heather Carey, Jennifer Roche-Desilets & Christopher J. Burant. (2021) Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients. Comprehensive Psychiatry 111, pages 152269.
Crossref
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Crossref
Meaghan RoachDee LinMarlon GrafPriti PednekarJacquelyn W ChouCarmela BensonJalpa A Doshi. (2021) Schizophrenia population health management: perspectives of and lessons learned from population health decision makers. Journal of Managed Care & Specialty Pharmacy 27:10-a Suppl, pages S2-S13.
Crossref
Crossref
Meaghan RoachDee LinMarlon GrafPriti PednekarJacquelyn W ChouCarmela BensonJalpa A Doshi. (2021) Schizophrenia population health management: perspectives of and lessons learned from population health decision makers. Journal of Managed Care & Specialty Pharmacy 27:10-a Suppl, pages S1-S13.
Crossref
Crossref
John Lauriello, Peter J. Weiden, Carole D. Gleeson, Ankit Shah, Luke Boulanger, Krutika Jariwala-Parikh, Elizabeth Hedgeman & Amy K. O’Sullivan. (2021) Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS Drugs 35:10, pages 1123-1135.
Crossref
Crossref
Christopher Evernden, Irene Giang & Mariah Anderson. (2021) The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia. Mental Health Clinician 11:5, pages 305-310.
Crossref
Crossref
Chiara Gobbicchi, Norma Verdolini, Giulia Menculini, Federica Cirimbilli, Daniela Gallucci, Eduard Vieta & Alfonso Tortorella. (2021) Searching for factors associated with the “Revolving Door phenomenon” in the psychiatric inpatient unit: A 5-year retrospective cohort study. Psychiatry Research 303, pages 114080.
Crossref
Crossref
Keisuke Takanobu, Daisuke Okazaki, Shinya Watanabe, Nobuyuki Mitsui & Teruaki Tanaka. (2021) Pulverizing medication as a harm reduction and intentional drug overdose prevention strategy: Two case studies. Neuropsychopharmacology Reports 41:3, pages 430-433.
Crossref
Crossref
Atsushi Kitamura, Takeshi Takagaki, Daisuke Nemoto, Yoshiko Tomita, Hironori Nishibe & Hiroyoshi Kakuyama. (2021)
Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D
2
Receptor Occupancy in Clinical Settings
. The Journal of Clinical Pharmacology 61:8, pages 1069-1080.
Crossref
Crossref
Karan Kverno & Ilya Rozenberg. (2021) Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia: Practical Considerations. Journal of Psychosocial Nursing and Mental Health Services 59:7, pages 7-12.
Crossref
Crossref
Dulcinea Vega, Francisco J. Acosta & Pedro Saavedra. (2021) Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study. Comprehensive Psychiatry 108, pages 152240.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2021) Oral Versus Long-Acting Injectable Antipsychotic Treatment for People With Severe Schizophrenia. Journal of Nervous & Mental Disease 209:5, pages 330-335.
Crossref
Crossref
Asta Ratna Prajapati, Alexandra Dima, George Mosa, Sion Scott, Fujian Song, Jonathan Wilson & Debi Bhattacharya. (2021) Mapping modifiable determinants of medication adherence in bipolar disorder (BD) to the theoretical domains framework (TDF): a systematic review. Psychological Medicine 51:7, pages 1082-1098.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Mehmet Hamdi ÖRÜM. (2021) Paliperidon Palmitat Aylık Uzun Etkili Enjeksiyon Kullanan Şizofreni ve Bipolar Bozukluk Tip 1 Tanılı Hastaların İncelenmesiExamination of Patients Diagnosed with Schizophrenia and Bipolar Disorder Type 1 Using Paliperidone Palmitate Once-Monthly Long-Acting Injectable. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi 54:1, pages 90-95.
Crossref
Crossref
Arnold P. M. van der Lee, Ibrahim Önsesveren, André I. Wierdsma, Roos van Westrhenen, Aartjan T. F. Beekman, Lieuwe de Haan & Niels C. L. Mulder. (2021) The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study. CNS Drugs.
Crossref
Crossref
Kanglai Li, Yingtao Liao, Zhihua Yang, Caishuang Yang, Minhua Chen, Xiuhua Wu & Zhaoyu Gan. (2021) Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance. Frontiers in Psychiatry 11.
Crossref
Crossref
José Manuel Olivares, Ana González-Pinto & Mario Páramo. (2021) Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European Psychiatry 64:1.
Crossref
Crossref
Silvia Díaz-Fernández, Francisco López-Muñoz & Juan J. Fernández-Miranda. (2021) Psychosocial and Pharmacological Approaches for Improving Treatment Adherence and Outcomes in People With Severe Schizophrenia: A 10-Year Follow-up. Journal of Psychiatric Practice 27:6, pages 417-426.
Crossref
Crossref
Ching-Hua Lin, Hung-Yu Chan, Chun-Chi Hsu & Feng-Chua Chen. (2021) Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics. Journal of Affective Disorders 279, pages 292-298.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics. Clinical Drug Investigation 41:1, pages 99-113.
Crossref
Crossref
Jessica M. Gannon, Judith Conlogue, Robin Sherwood, Jessica Nichols, Juliette R. Ballough, Noreen M. Fredrick & K.N. Roy Chengappa. (2020) Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions. Schizophrenia Research 222, pages 532-533.
Crossref
Crossref
Julia Kim & Philip Gerretsen. (2020) Improving insight to facilitate antipsychotic medication adherence in patients with schizophrenia. Clinical Neurophysiology 131:8, pages 1968-1970.
Crossref
Crossref
Nakao Iwata, Ataru Inagaki, Hiromi Sano, Kazunari Niidome, Yoshitsugu Kojima & Sakiko Yamada. (2020) Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in Therapy 37:7, pages 3324-3336.
Crossref
Crossref
Azita Alipour, Stephen Gabrielson & Puja Baldev Patel. (2020) Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness. Pharmacy 8:2, pages 103.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clinical Drug Investigation 40:4, pages 355-375.
Crossref
Crossref
Emmanuel Stip, Syed Javaid, Jonathan Bayard-Diotte, Karim Abdel Aziz & Danilo Arnone. (2020) Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry. Therapeutic Advances in Psychopharmacology 10, pages 204512532095711.
Crossref
Crossref
Donica Janzen, James Bolton, I fan Kuo, Christine Leong & Silvia Alessi-Severini. (2020) Trends in the Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada. Journal of Clinical Psychopharmacology 40:1, pages 6-13.
Crossref
Crossref
Linnea Stenmark, Katarzyna Popiolek, Robert Bodén, Ole Brus, Åsa Hammar, Mikael Landén, Johan Lundberg, Pia Nordanskog & Axel Nordenskjöld. (2020) Predictors of Treatment Response to Electroconvulsive Therapy in Schizophrenia—A Nationwide Registry-Based Study. Schizophrenia Bulletin Open 1:1.
Crossref
Crossref
Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews & Bernardo Soares. (2019) Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Brazilian Journal of Psychiatry 41:6, pages 499-510.
Crossref
Crossref
Anne E. Leighty & Elayne D. Ansara. (2019) Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans. Mental Health Clinician 9:6, pages 392-396.
Crossref
Crossref
Anne Andorn, Jay Graham, John Csernansky, John W. Newcomer, Sunita Shinde, Gilbert Muma, Christian Heidbreder & Maurizio Fava. (2019) Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology 39:5, pages 428-433.
Crossref
Crossref
Janet Sultana, Isabel Hurtado, Daniel Bejarano-Quisoboni, Francesco Giorgianni, Krista F. Huybrechts, Zhigang Lu, Elisabetta Patorno, Gabriel Sanfélix-Gimeno, Daniele Ugo Tari & Gianluca Trifirò. (2019) Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. European Journal of Clinical Pharmacology 75:7, pages 1005-1015.
Crossref
Crossref
Kamyar Keramatian, Trisha Chakrabarty & Lakshmi N. Yatham. (2019) Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review. CNS Drugs 33:5, pages 431-456.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Marit Tveito, Robert L. Smith, Espen Molden, Tore Haslemo, Helge Refsum, Cecilie Hartberg, Christoph U. Correll & Gudrun Høiseth. (2018) Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. Journal of Clinical Psychopharmacology 38:6, pages 570-576.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Maëlys Touya & Michael S Broder. (2018) Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder. Journal of Comparative Effectiveness Research 7:11, pages 1083-1093.
Crossref
Crossref
Ankit Shah, Lin Xie, Furaha Kariburyo, Qisu Zhang & Mugdha Gore. (2018) Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Advances in Therapy 35:11, pages 1994-2014.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in Therapy 35:10, pages 1612-1625.
Crossref
Crossref
Paolo Girardi, Antonio Del Casale, Chiara Rapinesi, Georgios D. Kotzalidis, Francesca Splendori, Claudio Verzura, Giada Trovini, Serena Sorice, Dario Carrus, Iginia Mancinelli, Anna Comparelli, Sergio De Filippis, Antonio Francomano, Andrea Ballerini, Andrea Marcellusi, Francesco S. Mennini, Giuseppe Ducci, Gabriele Sani, Maurizio Pompili & Roberto Brugnoli. (2018) Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Human Psychopharmacology: Clinical and Experimental 33:3, pages e2658.
Crossref
Crossref